Given the cross-sectional character of the most relevant studies, it is difficult to conclude if the increase in vaspin levels simply represents a counter-regulatory mechanism to insulin resistance or if it is causally associated with metabolic disturbances, and thus if by decreasing circulating vaspin an improvement in cardiometabolic outcomes is feasible. This evidence concerns the gene SERPINA12 and Insulin resistance.